Compliance in gout patients

Acta Reumatologica Portuguesa

Volumn 35, Issue 4, 2010, Pages 466-474

  Silva, Lígia ^a   De Miguel, Eugenio ^b   Peiteado, Diana ^b   Villalba, Alejandro ^b   Mola, Martin ^b   Pinto, José ^a   Ventura, Francisco S ^a  

^a University of Porto   (Portugal)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Adherence; Compliance; Gout; Serum uric acid; Ultrasound

Indexed keywords

ARTICLE; FEMALE; GOUT; HUMAN; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RISK FACTOR; STATISTICS;

FEMALE; GOUT; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 79251475897     PISSN: 0303464X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Mikuls TR. Quality of care in gout: from measurement to improvement. Clin Exp Rheumatol 2007;25:114-119.
2. Perez-Ruiz F, Lioté F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum 2007;57:1324-1328.
3. Baker JF, Ralph Schumacher H. Update on gout and hyperuricemia. Int J Clin Pract (published online) 2009 Nov.doi:10.1111/j.l742-1241.2009.02188.x
4. Doherty M. New insights into the epidemiology of gout. Rheumatology (Oxford) 2009;48:2-8.
5. Gibson T. Cristal-related arthropathies. In: Hochberg M, Silman A et al, ed. Rheumatology. 4th ed. Mosby Elsevier; 2008. 2: p l805-1837.
6. Ioachimescu AG, Brennan DM, Hoar BM, Hazen SL, Hoogwerf BJ. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum 2008;58:623-630.
7. Harrold LR, Andrade SE, Briesacher BA et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 2009; 11:R46.
8. Halpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Curr Med Res Opin 2009;25:1711-1719.
9. Terkeltaub R, Zelman D, Scavulli J, Perez-Ruiz F, Lioté F. Gout Study Group: Update on hyperuricemia and gout. Joint Bone Spine 2009;76:444-446.
10. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004;51:321-325.
11. Harrold LR, Andrade SE. Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. Semin Arthritis Rheum 2009;38:396-402.
12. de Klerk E, van der Heijde D, Landewé R, van der Tempel H, Urquhart J, van der Linden S. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003;30:44-54.
13. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008;28:437-443.
14. Harrold LR, Andrade SE, Briesacher B et al. The dynamics of chronic gout treatment: medication gaps and return to therapy. Am J Med 2010; 123:54-59.
15. Riedel AA, Nelson M, Joseph-Ridge N, Wallace K, MacDonald P Becker M. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004;31:1575-1581.
16. D. Peiteado Lopez, A. Villalba, E. De Miguel, M.C. Ordoñez, E. Martín Mola. Longitudinal study of ultraso-nography sensibility to change in patients with gout after one year of treatment. Ann Rheum Dis 2010;69:713.
17. Wallace S L, Robinson H, Masi A T, Decker J L, McCarty D J, Yu T E. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.
18. Zhang W Doherty M, Pascual E et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1301-1311.
19. Pillinger MH, Keenan RT. Update on the management of hyperuricemia and gout. Bull NYU Hosp Jt Dis 2008;66:231-239.
20. Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006;12:61-65.
21. Singh JA. Quality of life and quality of care for patients with gout.Curr Rheumatol Rep 2009; 11:154-160.
22. Singh JA, Hodges JS, Asch SM. Opportunities for improving medication use and monitoring in gout. Ann Rheum Dis 2009;68:1265-1270.
23. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15:565-74; discussion 575-7.
24. Zhang W, Doherty M, Bardin T et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-1324.
25. Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatology (Oxford) 2009;48:ii9-iil4.
26. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:356-360.
27. Hershfield MS. Reassessing serum urate targets in the management of refractory gout: can you go too low? Curr Opin Rheumatol 2009;21:138-142.
28. Thiele RG, Schlesinger N. Diagnosis of gout by ultrasound. Rheumatology 2007; 46:1116-1121.
29. Carter JD, Kedar RP, Anderson SR et al. An analysis of MRI and ultrasound imaging in patients with gout who have normal plain radiographs. Rheumatology (Oxford) 2009;48:1442-1446.
30. Perez-Ruiz F, Dalbeth N, Urresola A, De Miguel E, Schlesinger N. Imaging of Gout: findings and utility. Arthritis Research & Therapy 2009;11:232-239.
31. Li-Yu J, Clayburne G, Sieck M et al. Treatment of chronic gout. Can we determine when urate stores are de pleted enough to prevent attacks of gout? J Rheumatol 2001;28:577-5780.
32. Becker MA, Schumacher HR Jr. Wortmann RL etal. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-2461.